ライフサイエンスコーパス: serum creatinine

1 ization for heart failure, ESRD, or doubling serum creatinine.

2 e depletion, proteinuria, and an increase in serum creatinine.

3 as at least two-fold increase from baseline serum creatinine.

4 was 39% among 50,314 patients with available serum creatinine.

5 ce methods employed for the determination of serum creatinine.

6 ecreased creatinine clearance, and increased serum creatinine.

7 death-censored graft failure or doubling of serum creatinine.

8 onward, with documented baseline weight and serum creatinine.

9 endpoint of death, ESRD, and 50% increase in serum creatinine.

10 levated at earlier time points compared with serum creatinine.

11 in estimated glomerular filtration rate from serum creatinine, 0.01 g/dl (95% CI 0.0004-0.02; p < 0.0

12 Neurological and renal impairments (serum creatinine, 0.87+/-0.20; median, 0.80; interquarti

13 throughout the follow-up (36 months post KT: serum creatinine, 1.18 mg/dL).

14 d comparable HBA1c (0.06 vs. 0.05; P = 0.8), serum creatinine (116.6 mumol/L v 131.7 mumol/L; P = 0.0

15 6 months after transplantation predicted the serum creatinine 2 years after transplantation.

16 liver disease era (68% vs. 82%; P = 0.0001), serum creatinine (2.9+/-1.9 vs. 4.3+/-2.5; P < 0.0001),

17 ed nephropathy was defined as an increase in serum creatinine 50% above the baseline or an absolute i

18 2 weeks after transplantation predicted the serum creatinine 6 months and the estimated creatinine c

19 Daily peak serum creatinine (adjusted for baseline) values were als

20 tubular injury, tubular cell apoptosis, and serum creatinine after ischemia/reperfusion compared wit

21 Most estimates of GFR are based on serum creatinine, after adjusting for age, race, sex, an

22 1.7% for >/=30% decline in eGFR, doubling of serum creatinine, AKI, and kidney failure, respectively.

23 uated multiple organ injury as determined by serum creatinine, alanine aminotransferase, lactate dehy

24 achieved SVR12 experienced an improvement in serum creatinine and a reduction in proteinuria.

25 Limitation: Serum creatinine and albuminuria were measured only once

26 , animals transplanted with NEVKP grafts had serum creatinine and blood urea nitrogen values comparab

27 Changes in both serum creatinine and blood urea nitrogen were similar in

28 ed with SCS grafts had persistently elevated serum creatinine and blood urea nitrogen when compared w

29 oxication routes caused similar increases in serum creatinine and blood urea nitrogen, indicative of

30 n stage 3 acute kidney injury and daily peak serum creatinine and both delirium and coma.

31 en 2008 and 2011, had available preadmission serum creatinine and BP measures, and were not known to

32 Early and frequent measurements of serum creatinine and calculation of the creatinine reduc

33 Ps (rs3811321 and rs6565887) associated with serum creatinine and clinical outcome.

34 ated glomerular filtration rate (eGFR) using serum creatinine and cystatin C concentrations, and micr

35 GFR in subjects without cirrhosis using both serum creatinine and cystatin C levels.

36 inally, by functional markers of filtration (serum creatinine and cystatin C).

37 of aliskiren on renal outcomes (doubling of serum creatinine and end-stage renal disease) when used

38 uction in neutrophil levels and increases in serum creatinine and low-density lipoprotein cholesterol

39 quency of deaths, serious adverse events, or serum creatinine and phosphorus abnormalities between th

40 Higher serum creatinine and potassium levels were also observed

41 For initial assessment of GFR, measuring serum creatinine and reporting estimated GFR based on se

42 gnificantly decreased ectopic calcification, serum creatinine and serum phosphorus levels, circulatin

43 To evaluate guideline-concordant testing for serum creatinine and serum potassium within 180 days bef

44 ing the difference between baseline and peak serum creatinine and staged according to Kidney Disease

45 d 24 h after reperfusion for renal function (serum creatinine and urea), complement deposition (C3b/c

46 died 1,243 patients and classified AKI using serum creatinine and urine output.

47 We classified patients by levels of serum creatinine and/or urine output according to Kidney

48 donors (111 had AKI, defined as doubling of serum creatinine) and ascertained outcomes in the corres

49 ns must rely collectively on platelet count, serum creatinine, and ADAMTS13 activity in the context o

50 risks of >/=30% decline in eGFR, doubling of serum creatinine, and AKI; however, apixaban did not hav

51 end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause mortality-singly and as

52 lipocalin (NGAL), kidney injury molecule-1, serum creatinine, and clinical variables.

53 gher oxygen extraction, a lower decrement of serum creatinine, and higher levels of NGAL and ET-1 wer

54 and increased levels of liver transaminases, serum creatinine, and pancreatic enzymes.

55 developed septic shock, oliguria, increased serum creatinine, and reduced creatinine clearance (AKI)

56 mproved the prediction of DGF, whereas NGAL, serum creatinine, and the creatinine reduction ratio did

57 ns, including incidence of ESRD, doubling of serum creatinine, and the slopes of eGFR) were examined

58 In Raynaud phenomenon, male sex, age, and serum creatinine are related to mortality.

59 This is partly because the use of serum creatinine as the comparator has several limitatio

60 KI requires treating or preventing a rise in serum creatinine as well as the immediate and remote cli

61 t survival was significantly associated with serum creatinine at 6 months after transplantation and m

62 1), arterial hypertension (P < 0.05), higher serum creatinine at baseline (P < 0.001), and being on t

63 0.0001) as well as smaller mean increases in serum creatinine at week 48 (0.01 mg/dL [0.00-0.02] vs 0

64 sitivity at 0.95 specificity), compared with serum creatinine (AUC, 0.76; 95% CI: 0.64-0.87; 0.08 sen

65 It causes benign elevations in serum creatinine based on its inhibition of tubular crea

66 e or type, treatment duration, age, baseline serum creatinine, bilirubin or albumin, baseline mean ar

67 in posttransplant survival, lower levels of serum creatinine, blood urea nitrogen, phosphorus and ma

68 Serum creatinine, BUN, folate and vitamin B12, and blood

69 found between tHcy level and recipients age, serum creatinine, BUN, folate concentrations, and creati

70 In contrast with serum creatinine, C-mannosyltryptophan and pseudouridine

71 Acute CIN was defined as an increase in serum creatinine concentration >25% from the baseline va

72 Two metrics, a rise in serum creatinine concentration and a decrease in urine o

73 However, mean serum creatinine concentration and albuminuria remained

74 s were compared with adjustment for baseline serum creatinine concentration and changes in estimated

75 lt intake, ES rats still showed a lower mean serum creatinine concentration and less albuminuria, as

76 od cell casts in the urine, and/or a rise in serum creatinine concentration attributed to vasculitis)

77 group (RR, 1.61 [0.86 to 3.01]; P = .15) and serum creatinine concentration increased by a median of

78 ienced AKI defined using observed changes in serum creatinine concentration measured during hospitali

79 iltration rate, manifested by an increase in serum creatinine concentration or oliguria, and classifi

80 Current expressions based on serum creatinine concentration overestimate kidney funct

81 sensitive predictor of patient outcome than serum creatinine concentration post-APAP overdose.

82 AKI was defined as rise in serum creatinine concentration to 1.5-fold above baselin

83 njury defined as an increase of 0.3 mg/dL in serum creatinine concentration within 48 hours of surger

84 biomarker used to report kidney dysfunction (serum creatinine concentration) has suboptimal sensitivi

85 However, serum creatinine concentration, albuminuria, and glomeru

86 entricular tachycardia, atrial fibrillation, serum creatinine concentration, digoxin or amiodarone us

87 nal hazard model adjusted for age, diabetes, serum creatinine concentration, urinary albumin concentr

88 performance to predict outcome compared with serum creatinine concentration.

89 l, non-progressive increase from baseline in serum creatinine concentration.

90 an 25% or greater than 0.5 mg/dL increase in serum creatinine concentration.

91 and vAKI that induced a similar increase in serum creatinine concentration.

92 POL1 2-renal-risk-variant kidneys, follow-up serum creatinine concentrations were higher than that in

93 e obtained data on age, sex, height, weight, serum creatinine concentrations, and results for GFR fro

94 function [DGF] before day 90) were recorded; serum creatinine (Cr) at day 90 was defined as baseline.

95 ing or computed tomography (CT) and for whom serum creatinine (Cr) levels were obtained within 72 hou

96 ons incorporating both cystatin C (CysC) and serum creatinine (Creat) in living kidney donors has not

97 ing Kidney Disease/Improving Global Outcomes serum creatinine criteria.

98 tion as evidenced by significant decrease in serum creatinine (CsA 0.79 +/- 0.02 mg/dL vs CsA + DMF 0

99 Serum creatinine, cytomegalovirus, BK viremia, or BK nep

100 At 24 hours after reperfusion, serum creatinine decreased in postcond-CsA and IPC compa

101 Increases in serum creatinine (DeltaSCr) from baseline signify acute

102 of histopathologic findings, with increased serum creatinine detected only in the ReninAAV-treated d

103 donor and recipient age and sex, ethnicity, serum creatinine, diabetes mellitus, and heart failure c

104 level and renal events (doubling of baseline serum creatinine, dialysis, or kidney transplantation) i

105 mary renal end points consisted of sustained serum creatinine doubling and/or ESRD requiring long-ter

106 utcome (change in proteinuria or doubling of serum creatinine [DSCR]) for ESRD during a >/=1-year fol

107 t did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of 4.

108 atinine and reporting estimated GFR based on serum creatinine (eGFRcr) using the Chronic Kidney Disea

109 and reported using cystatin C (eGFRcys) and serum creatinine (eGFRcr-cys) or GFR should be measured

110 Clinical AKI, measured by serum creatinine elevation, is associated with long-term

111 ITUDE was defined as a sustained doubling of serum creatinine, end-stage renal disease, or renal deat

112 tic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated

113 tcomes included CKD progression (doubling of serum creatinine/ESRD), CV events/CV death, and a compos

114 ratio >30 mg/g), and chronic kidney disease (serum creatinine estimated glomerular filtration rate [e

115 gnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate,

116 ted hemoglobin (HbA1c), blood urea nitrogen, serum creatinine, estimated glomerular filtration rate,

117 ine whether urinary beta2M, urinary protein, serum creatinine, estimated glomerular filtration rate,

118 While serum creatinine fell at 12 hours, serum cystatin C incr

119 ed as a >/= 50% or >/= 0.3-mg/dl increase in serum creatinine from baseline.

120 Mean decrease in serum creatinine from biopsy to 1 month after rejection

121 filtration rate in patients with stabilized serum creatinine (grade A).

122 repeats), and defined AKI as an increase in serum creatinine >/=0.3 mg/dl within 48 hours or >/=50%

123 CI-AKI was defined as an increase in serum creatinine >/=0.5 mg/dl above baseline within 3 da

124 ell count >/=15 000 cells/mL, age >60 years, serum creatinine >/=1.5 times baseline, or temperature >

125 rtality, use of RRT, and persistent elevated serum creatinine >/=200% from baseline at hospital disch

126 renal function was defined as an increase of serum creatinine >0.3 mg/dL and a change of >/=25%.

127 mal) or a renal safety event (an increase in serum creatinine >1.5 times the baseline value or a new

128 ltivariate analysis, age >70 years (P=0.01), serum creatinine >115 mumol/L (P=0.0003), and individual

129 eria: (1) platelet count <100 x 10(9)/L, (2) serum creatinine >2.25 mg/dL, and (3) a disintegrin and

130 However, an increase in serum creatinine >25% from the baseline value to 30 day

131 [CI]: 0.66 to 0.89; p < 0.001), doubling of serum creatinine (HR: 0.62; 95% CI: 0.40 to 0.95; p = 0.

132 Four grade 3 events (elevated serum creatinine in a patient with baseline renal insuff

133 The elevated level of serum creatinine in CNI groups was abolished by Aliskire

134 ly lowered levels of blood urea nitrogen and serum creatinine in rats with renal ischemia-reperfusion

135 However, we noted significant improvement in serum creatinine in the hypomorphs at 3 and 10 days afte

136 nsplantation in 2002, the heavy weighting of serum creatinine in the model for end-stage liver diseas

137 quality improvement study to prevent CI-AKI (serum creatinine increase >/=0.3 mg/dL within 48 hours o

138 d acute kidney injury (CI-AKI), defined as a serum creatinine increase >/=0.5 mg/dL or >/=25% within

139 Primary end point was AKI (serum creatinine increase >/=0.5 mg/dL).

140 Primary end points were AKI (serum creatinine increase >0.5 mg/dL) and all-cause in-h

141 ation with acute kidney injury (defined by a serum creatinine increase during hospitalization > 0.3 m

142 y Network criteria: stage 1 was defined as a serum creatinine increase greater than or equal to 0.3 m

143 o- to three-fold from baseline; stage 3 as a serum creatinine increase greater than three-fold from b

144 ual to 0.3 mg/dL from baseline; stage 2 as a serum creatinine increase greater than two- to three-fol

145 e, 3 events-syncope, pulmonary embolism, and serum creatinine increase-in 3 patients were determined

146 Serum creatinine increased from 1.7+/-0.4 mg/dL at 3 mon

147 Persistent congestion trumps serum creatinine increases in predicting adverse heart f

148 r alafenamide had significantly smaller mean serum creatinine increases than those given E/C/F/tenofo

149 s required because of conditions that affect serum creatinine independent of GFR (eg, extremes of mus

150 An increase in serum creatinine led to the addition of sirolimus at 3 m

151 e kidney injury ( AKI acute kidney injury ) (serum creatinine level >/= 0.5 mg/dL [44.2 mumol/L] abov

152 calciphylaxis without severe kidney disease (serum creatinine level >3 mg/dL; glomerular filtration r

153 005), as well as higher risks of an elevated serum creatinine level (4.1% vs. 2.7%, P=0.009) and an e

154 a significantly elevated risk of doubling of serum creatinine level (HR, 1.53; 95% CI, 1.42 to 1.65),

155 placebo, reduced risk of acute elevation in serum creatinine level (pooled relative risk, 0.57; 95%

156 lacebo, increased risk of acute elevation in serum creatinine level (pooled relative risk, 1.52; 95%

157 Median baseline serum creatinine level (range) was 1.4 (0.8-2.4) mg/dl,

158 s that altered risk for an acute increase in serum creatinine level and had reported between-group di

159 t-term effects of interventions on change in serum creatinine level and more meaningful clinical outc

160 ase in albumin-to-creatinine ratio (ACR) and serum creatinine level and more severe renal lesions.

161 ups, as soon as day 12 with no difference in serum creatinine level and proteinuria at 1, 3, 6, and 1

162 o AKI to 51.1% and 55.3%, respectively, when serum creatinine level and urine output both indicated s

163 RRT is greatest when patients meet both the serum creatinine level and urine output criteria for AKI

164 value of using small to moderate changes in serum creatinine level as end points in clinical trials.

165 ncrease of at least 50% from baseline in the serum creatinine level at 90 days.

166 arly acute kidney injury (>/=50% increase of serum creatinine level from baseline or oliguria for >/=

167 g KDIGO criteria and was based on changes in serum creatinine level from hospital days 0 to 2 through

168 dialysis session within the first week or a serum creatinine level greater than 200 mumol/L at day 7

169 ld to moderate, often temporary elevation in serum creatinine level in placebo-controlled randomized

170 Doubling of the serum creatinine level occurred in 70 of 4645 patients (

171 rum creatinine level of at least 2-fold or a serum creatinine level of >/=3.96 mg/dL with an increase

172 % women per cohort) had a mean (SD) baseline serum creatinine level of 1.0 (0.2) mg/dL and more than

173 n the incidence of serious adverse events, a serum creatinine level of 3.0 mg per deciliter (265 mumo

174 ) (normal level, <142 U/L [2.37 mukat/L]), a serum creatinine level of 93 mumol/L (reference range, 7

175 n of patients with AKI (defined as a rise in serum creatinine level of at least 2-fold or a serum cre

176 Secondary outcomes were doubling of serum creatinine level or AKI-RRT, as well as AKI-RRT or

177 s determined by the magnitude of increase in serum creatinine level or decrease in urine output.

178 d that a small increase in the postoperative serum creatinine level was associated with an almost 3-f

179 ound that GFR was significantly greater, and serum creatinine level was significantly lower in TRPC6

180 s of estimated glomerular filtration rate or serum creatinine level were included in 10 studies (17 m

181 tine laboratory tests (complete blood count, serum creatinine level), urine albumin/creatinine ratio

182 ular filtration rate (eGFR), doubling of the serum creatinine level, acute kidney injury (AKI), and k

183 orated STAT activity and resulted in reduced serum creatinine level, albuminuria, and renal histologi

184 ates, including acute rejection, doubling of serum creatinine level, and eGFR at year 1 or year 2.

185 In adjusted analysis, higher serum creatinine level, black race, older age, and ische

186 macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or deat

187 ression to macroalbuminuria, doubling of the serum creatinine level, initiation of renal-replacement

188 ansgenic mice also significantly ameliorated serum creatinine level, proteinuria, tubular injury, and

189 Thus, the outcome of acute change in serum creatinine level, regardless of underlying biology

190 rease from the preoperative to postoperative serum creatinine level.

191 spironolactone was associated with increased serum creatinine levels and a doubling of the rate of hy

192 It was associated with increased serum creatinine levels and higher mortality rates in pa

193 These data suggest that urinary beta2M and serum creatinine levels are sensitive and relatively sim

194 The serum creatinine levels at 3 months were 1.2 mg/dl in th

195 l and statistically significant decreases in serum creatinine levels compared with levels in animals

196 d antidonor skin graft responses, and normal serum creatinine levels despite withdrawal of all medica

197 recipient had immediate graft function with serum creatinine levels falling from 315 to 105 micromol

198 buminuria, proteinuria, serum cystatin C, or serum creatinine levels in TxNIP(-/-) mice.

199 Serum creatinine levels increased from baseline (18.8 +/

200 s with underlying kidney disease or abnormal serum creatinine levels on hospital days 0 to 2 were amo

201 Serum creatinine levels remained stable throughout the t

202 e (connexin 43+/-) had proteinuria, BUN, and serum creatinine levels significantly lower than those o

203 in a subpopulation for which information on serum creatinine levels was available (5.46% vs. 3.34%;

204 The mean serum creatinine levels were identical between the two g

205 Serum creatinine levels were measured weekly to monitor

206 Elevations of serum creatinine levels were seen more frequently among

207 ital diagnosis code and, in a subpopulation, serum creatinine levels) within 90 days of prescription

208 i-alphavbeta5 antibody significantly reduced serum creatinine levels, diminished renal damage detecte

209 The two groups had comparable serum creatinine levels, estimated glomerular filtration

210 Increased serum creatinine levels, high serum titers of donor-spec

211 ficant reductions in cystic disease, BUN and serum creatinine levels.

212 M levels, and 10 patients (22%) had elevated serum creatinine levels.

213 eters: presentation at time of index biopsy, serum creatinine levels/renal function over 24 months of

214 nts during previous 24 hours (<10 vs >/=10), serum creatinine leves (<1.2 mg/dL vs >/=1.2 mg/dL) and

215 n function (serum bilirubin </=3.0 mg/dL and serum creatinine </=3.0 mg/dL, unless higher concentrati

216 ubin, nosocomial infection, and reduction in serum creatinine <0.3 mg/dL at day 3 of antibiotic treat

217 rcumference >94 (males) or >80 (females) cm, serum creatinine <1.2 mg/dL, and normoalbuminuria were r

218 ncluded systolic blood pressure>/=140 mm Hg, serum creatinine<1.0 mg/dL, QRS 130 to 160 ms, and nonis

219 nely screen or monitor bone mineral density, serum creatinine, magnesium, or vitamin B12.

220 The determination of serum creatinine may be affected by the interconversion

221 mated reporting of estimated GFR (eGFR) with serum creatinine measurement is now common.

222 and control groups had similar prepregnancy serum creatinine measurements (0.70+/-0.20 versus 0.69+/

223 of proteinuria and three or more outpatient serum creatinine measurements over a period of >/=1 year

224 ology Collaboration equation from calibrated serum creatinine measurements.

225 gression was defined as doubling of baseline serum creatinine (MMKD-Study) and/or end stage renal dis

226 vents (n = 53), graft failure or doubling of serum creatinine (n = 140), noncardiovascular mortality

227 tion (MI) with atrial fibrillation and known serum creatinine (N = 24,317), including 21.8% who were

228 Northern California cohort by an increase in serum creatinine of >/=0.3 mg/dl or >/=150% above baseli

229 were treated for diabetes at year 1, or had serum creatinine of 130 mumol/L or higher at year 1.

230 afts preserved with NEVKP demonstrated lower serum creatinine on days 1 to 7 (P < 0.05) and lower pea

231 use of ureteral stent; total ischemia time; serum creatinine on discharge; and need for temporary po

232 erence in incidence rates for an increase in serum creatinine or a new requirement for renal replacem

233 ed as the composite of confirmed doubling of serum creatinine or ESRD.

234 he neonatal intensive care unit; doubling of serum creatinine or increase in CKD stage.

235 ge 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4), and cumulative pre-stage 1

236 Serum creatinine (P = 0.005), ascites as indication for

237 roups in terms of any demographic variables, serum creatinine, panel reactive antibody levels, donor-

238 NEVKP versus SCS grafts demonstrated similar serum creatinine peak levels (NEVKP, 2.0 +/- 0.5 vs SCS

239 Serum creatinine peaked late (24 hr), when clinical reco

240 Blood eosinophilia and elevated serum creatinine phosphokinase (CPK) levels were observe

241 serum cystatin C (Pnoninferiority < 0.0001), serum creatinine (Pnoninferiority = 0.0004), and measure

242 imary outcome was AKI defined as the rise in serum creatinine post procedure >/=0.5 mg/dL or >/=25% a

243 Sirolimus replaced tacrolimus if serum creatinine remained above 2.0 mg/dL by day 7.

244 ute kidney injury defined as a postoperative serum creatinine rise from preoperative baseline by 50%

245 fined using a standardized definition -i.e., serum creatinine rise of >/=0.3 mg/dL (26.5 mcmol/L) or

246 When serum creatinine (SC) and UO criteria were used, 604 pat

247 kidney injury (AKI) is defined by changes in serum creatinine (SCr) and diuresis with risk/injury/fai

248 etter glomerular filtration rate marker than serum creatinine (SCr) and may improve AKI definition.

249 Complete response was defined by decrease of serum creatinine (sCr) from baseline to a final value </

250 Renal Disease (MDRD) performance to predict serum creatinine (SCr) in severe trauma population and d

251 /=25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3-3.3 mg/dl for women

252 --defined as an increase in maximal observed serum creatinine (SCr) level of either (a) >/=0.5 mg/dL

253 Knowledge of an optimal expected serum creatinine (SCr) would be useful to detect early r

254 e variants have been found to associate with serum creatinine (SCr), estimated glomerular filtration

255 Posttransplant monitoring included serum creatinine (SCr), peripheral T-regulatory cells (p

256 ) is based on objective variables, including serum creatinine (SCr).

257 -specific antibodies (DSA) and acute rise in serum creatinine (SCr).

258 >0.5 mg/dl) or a relative (>25%) increase in serum creatinine (sCr).

259 , which was reflected by similarly increased serum creatinine (SCr; approximately 4.5 mg/dl) at 2 day

260 resholds in predicting contrast-induced AKI (serum creatinine [sCr] increase >/=0.3 mg/dL at 48 hours

261 Incidence of AKI (serum creatinine [SCr] increase of >/=0.5 mg/dL [>/=44.2

262 confirmed HRS reversal (CHRSR, defined as 2 serum creatinine [SCr] values </=1.5 mg/dL, at least 40

263 ower rate of decline of serum urea nitrogen, serum creatinine, serum uric acid, and serum phosphorus;

264 bilistic model optimized for nonlinearity of serum creatinine time series that calculates the risk fu

265 ing the measurement of cystatin C to that of serum creatinine to determine the estimated glomerular f

266 Using Pearson's correlation coefficient, serum creatinine-to-serum cystatin C ratio was found to

267 mide pulses or in case of return to baseline serum creatinine together with reduction of donor-specif

268 1000597 was associated with higher levels of serum creatinine, uric acid, calcium and lower urine pH

269 mptoms, including prostate-specific antigen, serum creatinine, urine cytology, imaging, cystourethros

270 Outcome measures included serum creatinine, urine microprotenuira, and immunohisto

271 models that included age, sex, and discharge serum creatinine value alone (integrated discrimination

272 values were more likely to have an abnormal serum creatinine value at baseline if they were non-Hisp

273 severity of acute kidney injury, and higher serum creatinine value at discharge.

274 study authors with an elevated preoperative serum creatinine value or a low estimated glomerular fil

275 come: older age, female sex, higher baseline serum creatinine value, albuminuria, greater severity of

276 can Americans and Hispanic/Latino Americans, serum creatinine values increased as African ancestry in

277 on the diagnosis of the index admission and serum creatinine values: 1) acute kidney injury, 2) pneu

278 Baseline serum creatinine was >/=110 mumol/l in 48% of patients i

279 Patients were excluded if their baseline serum creatinine was >1.2mg/dL or they were receiving re

280 l, septic, and recovery sheep, respectively, serum creatinine was (median) 82 (interquartile range, 7

281 Median baseline serum creatinine was 0.97 mg/dL (range 0.7-2.47).

282 Mean 6-month serum creatinine was 1.2 mg/dL.

283 Mean serum creatinine was 1.7+/-1 mg/dL in functioning grafts

284 of increased beta2M combined with increased serum creatinine was 100% for detecting definitive and/o

285 The last median serum creatinine was 128.2 +/- 40.8 mumol/L.

286 HIV testing was done monthly and serum creatinine was assessed every 3 months.

287 lomerular filtration rate based on admission serum creatinine was categorized as dichotomous (presenc

288 ted with markers of inflammatory state while serum creatinine was correlated with fat-free mass, whic

289 Serum creatinine was lower in TLR4 allografts at day 14

290 Serum creatinine was measured at each visit, and eGFR wa

291 Serum creatinine was measured.

292 tes after onset of therapy-induced increased serum creatinine was not superior to standard care and r

293 urs, a statistically significant decrease in serum creatinine was seen in two of the four high-dose C

294 At week 48, mean change in serum creatinine was small in both groups (tenofovir ala

295 systolic BP target with repeated measures of serum creatinine, we evaluated differences by study arm

296 from randomization to hospital discharge in serum creatinine were a lower baseline blood urea nitrog

297 In both sexes, patients' age and serum creatinine were associated with mortality.

298 Urinary beta2M, urinary protein, and serum creatinine were measured prospectively, and the es

299 ey disease (CKD) monitoring in primary care, serum creatinine with estimated glomerular filtration ra

300 ped sudden onset oliguria and rapidly rising serum creatinine with marked rebound of donor-specific a